Abstract

Amyotrophic lateral sclerosis (ALS) is a complex disease with a late onset and is characterized by the progressive loss of muscular and respiratory functions. Although recent studies have partially elucidated ALS’s mechanisms, many questions remain such as what the most important molecular pathways involved in ALS are and why there is such a large difference in ALS onset among different populations. In this study, we addressed this issue with a bioinformatics approach, using the United Kingdom Biobank (UKBB) and the European 1000 Genomes Project (1KG) in order to analyze the most ALS-representative single nucleotide polymorphisms (SNPs) that differ for minor allele frequency (MAF) between the United Kingdom population and some European populations including Finnish in Finland, Iberian population in Spain, and Tuscans in Italy. We found 84 SNPs associated with 46 genes that are involved in different pathways including: “Ca2+ activated K+ channels”, “cGMP effects”, ”Nitric oxide stimulates guanylate cyclase”, “Proton/oligopeptide cotransporters”, and “Signaling by MAPK mutants”. In addition, we revealed that 83% of the 84 SNPs can alter transcription factor-motives binding sites of 224 genes implicated in “Regulation of beta-cell development”, “Transcription-al regulation by RUNX3”, “Transcriptional regulation of pluripotent stem cells”, and “FOXO-mediated transcription of cell death genes”. In conclusion, the genes and pathways analyzed could explain the cause of the difference of ALS onset.

Highlights

  • Amyotrophic lateral sclerosis (ALS) is a complex and chronic disease with the onset of symptoms occurring generally between the ages of 50 and 65 [1,2,3,4,5]

  • single nucleotide polymorphisms (SNPs) Differ between United Kingdom Biobank (UKBB) and the European 1000 Genome

  • We reported a genome-wide association analysis between SNPs and ALS to identify those SNPs that could be involved in the different incidence of ALS between UK and some

Read more

Summary

Introduction

Amyotrophic lateral sclerosis (ALS) is a complex and chronic disease with the onset of symptoms occurring generally between the ages of 50 and 65 [1,2,3,4,5]. This disease involves motor neuron degeneration characterized by the progressive loss of upper and lower motor neurons at the bulbar and spinal levels [6]. Recent population-based motor neuron disease studies show a significant difference in the incidence of ALS between the world (0.6–2.1/100,000 person per year) and Europe (2.1–3.8/100,000 person per year) [15,16,17,18]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call